• Profile
Close

Intravenous iron dosing and infection risk in patients on hemodialysis: A prespecified secondary analysis of the PIVOTAL trial

Journal of the American Society of Nephrology Apr 10, 2020

Macdougall IC, Bhandari S, White C, et al. - In view of the data from experimental and observational studies raising concerns that intravenous (IV) iron might increase the risk of infections, researchers conducted a prespecified secondary analysis of the Proactive IV Iron Therapy in Haemodialysis Patients (PIVOTAL) trial to determine infection rates among 2,141 randomized patients who were undergoing maintenance hemodialysis for ESKD and were randomized to a high-dose or a low-dose IV iron regimen. No differences were observed in incidence of infection, hospitalization for infection, or death from infection between high-dose and low-dose IV iron groups. The PIVOTAL trial established the potential cardiovascular benefits of higher-dose IV iron (due to either a direct effect of the IV iron or a decreased use of erythropoiesis-stimulating agents and thus, less exposure to associated cardiotoxic effects). Outcomes of this analysis provides reassurance for providing higher doses of IV iron than are currently given in many units worldwide. A strong correlation was observed between the risk of a first cardiovascular event and a recent infection.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay